KN25-Treg (IL2Rα-biased IL2v)

---

KINE Biotech is leveraging its cytokine engineering platform to develop IL2Rα-biased IL2v variants designed to preferentially activate regulatory T cells (Tregs), which highly express the IL2Rα (CD25) subunit. By enhancing Treg expansion without broadly stimulating effector T cells, these IL2v molecules offer a targeted strategy to restore immune tolerance in autoimmune conditions. This selective mechanism contrasts with traditional IL-2 therapies, which often activate both regulatory and inflammatory pathways, leading to dose-limiting side effects. KINE’s IL2Rα-biased immunocytokines represent a promising new class of immune-suppressive biologics with potential applications across a range of autoimmune and inflammatory diseases.